These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 8682029)

  • 1. Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle. Implications for possible antiarrhythmic and proarrhythmic mechanisms.
    Katritsis D; Rowland E; O'Nunain S; Shakespeare CF; Poloniecki J; Camm AJ
    Eur Heart J; 1995 Dec; 16(12):1930-5. PubMed ID: 8682029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous flecainide acetate for supraventricular tachycardias.
    Hellestrand KJ
    Am J Cardiol; 1988 Aug; 62(6):16D-22D. PubMed ID: 3136630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the anti-arrhythmia effect of intravenous flecainide in supraventricular tachyarrhythmias].
    Garre L; Alvarez A; Cianciulli T; Quiroga J; Califano J; Mautner B
    Arch Inst Cardiol Mex; 1989; 59(3):241-4. PubMed ID: 2506843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac devices with class 1C antiarrhythmics: a potentially toxic combination.
    Apps A; Miller CP; Fellows S; Jones M
    BMJ Case Rep; 2015 Aug; 2015():. PubMed ID: 26286909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacology of modern anti-arrhythmia drugs in therapy of supraventricular tachycardia].
    Honerjäger P; Schmidt G
    Z Gesamte Inn Med; 1993 Sep; 48(9):425-9. PubMed ID: 8212747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Supraventricular tachycardia with wide QRS complexes during Vaughan-Williams class I anti-arrhythmic treatment. Diagnostic and therapeutic implications].
    Aouate P; Frank R; Fontaine G; Tonet J; Tageddine R; Benassar A; Turlure A; Jacquemin M; Laborde JP
    Arch Mal Coeur Vaiss; 1995 Dec; 88(12):1869-74. PubMed ID: 8729368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of long-term oral flecainide acetate in patients with responsive supraventricular tachycardia.
    Hellestrand KJ
    Am J Cardiol; 1996 Jan; 77(3):83A-88A. PubMed ID: 8607396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group.
    Hopson JR; Buxton AE; Rinkenberger RL; Nademanee K; Heilman JM; Kienzle MG
    Am J Cardiol; 1996 Jan; 77(3):72A-82A. PubMed ID: 8607395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class 1 antiarrhythmic drugs--characteristic electrocardiographic differences when assessed by atrial and ventricular pacing.
    Milne JR; Hellestrand KJ; Bexton RS; Burnett PJ; Debbas NM; Camm AJ
    Eur Heart J; 1984 Feb; 5(2):99-107. PubMed ID: 6723689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary delivery of flecainide causes a rate-dependent predominant effect on atrial compared with ventricular depolarization duration revealed by intracardiac recordings in an intact porcine model.
    de Antonio VZ; Silva AC; Stocco FG; Silva BA; Marum AA; Bortolotto AL; Belardinelli L; Verrier RL
    J Cardiovasc Electrophysiol; 2018 Nov; 29(11):1563-1569. PubMed ID: 30106207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of flecainide on termination of atrial flutter by rapid atrial pacing.
    Heldal M; Orning OM
    Eur Heart J; 1993 Mar; 14(3):421-4. PubMed ID: 8458365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
    Chimienti M; Cullen MT; Casadei G
    Eur Heart J; 1995 Dec; 16(12):1943-51. PubMed ID: 8682031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide.
    Taylor R; Gandhi MM; Lloyd G
    BMJ; 2010 Mar; 340():b4684. PubMed ID: 20219811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug.
    Crijns HJ; Van Gelder IC; Kingma JH; Dunselman PH; Gosselink AT; Lie KI
    Eur Heart J; 1994 Oct; 15(10):1403-8. PubMed ID: 7821320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human atrial repolarization: effects of sinus rate, pacing and drugs on the surface electrocardiogram.
    Debbas NM; Jackson SH; de Jonghe D; Robert A; Camm AJ
    J Am Coll Cardiol; 1999 Feb; 33(2):358-65. PubMed ID: 9973015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of intravenous flecainide in horses with naturally-occurring atrial fibrillation.
    van Loon G; Blissitt KJ; Keen JA; Young LE
    Equine Vet J; 2004 Nov; 36(7):609-14. PubMed ID: 15581326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm.
    Suttorp MJ; Kingma JH; Jessurun ER; Lie-A-Huen L; van Hemel NM; Lie KI
    J Am Coll Cardiol; 1990 Dec; 16(7):1722-7. PubMed ID: 2123909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects.
    Sihm I; Hansen FA; Rasmussen J; Pedersen AK; Thygesen K
    Eur Heart J; 1990 Feb; 11(2):145-8. PubMed ID: 2107078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
    Rinkenberger RL; Naccarelli GV; Berns E; Dougherty AH
    Am J Cardiol; 1988 Aug; 62(6):44D-55D. PubMed ID: 3136636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of QT dispersion during atrial fibrillation and sinus rhythm in the same patients, at normal and prolonged ventricular repolarization.
    Houltz B; Darpö B; Swedberg K; Blomström P; Crijns HJ; Jensen SM; Svernhage E; Edvardsson N
    Europace; 2000 Jan; 2(1):20-31. PubMed ID: 11225593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.